This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Leukemia	Bromodomain containing 2 (BRD2); BRD3; BRD4; myeloid-lymphoid or mixed-lineage leukemia (MLL; HRX)	<p>Mouse studies identified a new bromodomain inhibitor that could help treat leukemias characterized by MLL fusions. In MLL leukemia cell lines, I-BET151, an inhibitor of BRD2, BRD3 and BRD4, blocked proliferation at low nM concentrations. In two mouse models of MLL, I-BET151 decreased disease burden and increased survival compared with vehicle. Next steps include testing the inhibitor against additional malignancies.</p> <p>GlaxoSmithKline plc is investigating bromodomain inhibitors across a range of undisclosed indications.</p> <p><i>SciBX</i> 4(42); doi:10.1038/scibx.2011.1175 Published online Oct. 27, 2011</p>	Patent and licensing status undisclosed	<p>Dawson, M.A. <i>et al. Nature</i>; published online Oct. 2, 2011; doi:10.1038/nature10509 Contact: Tony Kouzarides, University of Cambridge, Cambridge, U.K. e-mail: t.kouzarides@gurdon.cam.ac.uk Contact: Mark A. Dawson, same affiliation as above e-mail: mafd2@cam.ac.uk Contact: Kevin Lee, GlaxoSmithKline plc, Stevenage, U.K. e-mail: kevin.2.lee@gsk.com</p>